Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)

Market Cap	9.42B +3.9%
Revenue (ttm)	15.94B -1.7%
Net Income	449.15M -26.7%
EPS	0.18 -25.1%
Shares Out	2.52B
PE Ratio	20.86
Forward PE	14.38
Dividend	n/a
Ex-Dividend Date	n/a

Volume	222,431,205
Average Volume	53,513,803
Open	3.870
Previous Close	3.870
Day's Range	3.710 - 3.950
52-Week Range	3.060 - 4.150
Beta	0.19
RSI	60.72
Earnings Date	Apr 23, 2026

About SHA:600664

Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, anti-virus and anti-infection, cerebrovascular, and cardiovascular diseases, as well as mineral and nutritional supplements, Chinese medicines, and antibiotics. It also provides calcium ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1991
• Employees: 10,180
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600664

Financial Performance

In 2024, SHA:600664's revenue was 16.18 billion, an increase of 4.65% compared to the previous year's 15.46 billion. Earnings were 628.85 million, an increase of 59.10%.